Wang Xinqiao, Yin Xue, Li Yuxin, Zhang Shuhui, Hu Meie, Wei Minjie, Li Zhenhua
School of Pharmacy, China Medical University, Shenyang, Liaoning Province, 110122, P.R. China.
Department of Pharmacy, The First Hospital of China Medical University, Shenyang, Liaoning Province, 110001, P.R. China.
J Nanobiotechnology. 2024 Dec 19;22(1):771. doi: 10.1186/s12951-024-02975-7.
Current standard-of-care therapies have failed to improve the survival of patients with metastatic pancreatic cancer (PCA). Therefore, exploring novel therapeutic approaches for cancer targeting is of utmost need. During the past few years, many efforts have been made to develop conventional treatment strategies to reduce chemotherapy resistance. However, critical challenges have impeded current cancer management outcomes, and limited clinical responses have been achieved due to unfavorable off-target effects. Advances in nanotechnology-based gene and immune-modulator delivery systems have excellent advantages for improving the therapeutic efficacy of PCA and provide promising avenues for overcoming the immunosuppressive tumor microenvironment and enhancing patient treatment outcomes. This review article provides insight into the challenges, opportunities, and future perspectives of these novel emerging nanoparticles based on lipid, polymer, and inorganic metal carriers to modulate genes and immunotherapy paradigms for PCA anticancer activity.
目前的标准治疗方案未能提高转移性胰腺癌（PCA）患者的生存率。因此，探索针对癌症的新型治疗方法迫在眉睫。在过去几年中，人们为开发传统治疗策略以降低化疗耐药性付出了诸多努力。然而，关键挑战阻碍了当前癌症治疗的效果，由于不良的脱靶效应，临床反应有限。基于纳米技术的基因和免疫调节剂递送系统的进展在提高PCA的治疗效果方面具有显著优势，并为克服免疫抑制性肿瘤微环境和提高患者治疗效果提供了有前景的途径。这篇综述文章深入探讨了这些基于脂质、聚合物和无机金属载体的新型纳米颗粒在调节基因和免疫治疗模式以实现PCA抗癌活性方面所面临的挑战、机遇和未来前景。
